Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease in Patients Who Received Anti-CD20 after Hematopoietic Stem Cell Transplantation.

Pagliuca S, Bommier C, Michonneau D, Meignin V, Salmona M, Robin M, Prata PH, Xhaard A, de Fontbrune FS, Feghoul L, Dhedin N, de Latour RP, Caillat-Zucman S, Goff JL, Socié G.

Biol Blood Marrow Transplant. 2019 Aug 14. pii: S1083-8791(19)30520-8. doi: 10.1016/j.bbmt.2019.08.006. [Epub ahead of print]

PMID:
31421238
2.

Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.

Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.

Ann Hematol. 2019 Sep;98(9):2163-2177. doi: 10.1007/s00277-019-03742-7. Epub 2019 Jun 26.

PMID:
31243569
3.

Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

Clin Infect Dis. 2013 Sep;57(6):794-802. doi: 10.1093/cid/cit391. Epub 2013 Jun 13.

PMID:
23771985
4.

Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes.

Xu LP, Zhang CL, Mo XD, Zhang XH, Chen H, Han W, Chen YH, Wang Y, Yan CH, Wang JZ, Wang FR, Zhao T, Liu YR, Liu KY, Huang XJ.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2185-2191. doi: 10.1016/j.bbmt.2015.07.035. Epub 2015 Aug 5.

5.

[Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].

Bao X, Zhu Q, Qiu H, Chen F, Xue S, Ma X, Sun A, Wu D.

Zhonghua Xue Ye Xue Za Zhi. 2016 Feb;37(2):138-43. doi: 10.3760/cma.j.issn.0253-2727.2016.02.011. Chinese.

PMID:
27014984
6.

Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.

Kobayashi S, Sano H, Mochizuki K, Ohara Y, Takahashi N, Ohto H, Kikuta A.

Pediatr Int. 2017 Sep;59(9):973-978. doi: 10.1111/ped.13336.

PMID:
28581032
7.

Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.

Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, Khan F, Taparia M, Jimenez-Zepeda VH, Stewart DA, Daly A, Storek J.

Clin Transplant. 2018 Jan;32(1). doi: 10.1111/ctr.13150. Epub 2017 Dec 1.

PMID:
29114932
8.

Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.

Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.

Transpl Infect Dis. 2016 Feb;18(1):44-54. doi: 10.1111/tid.12485. Epub 2016 Jan 30.

PMID:
26574232
9.
10.

Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.

Styczynski J, Einsele H, Gil L, Ljungman P.

Transpl Infect Dis. 2009 Oct;11(5):383-92. doi: 10.1111/j.1399-3062.2009.00411.x. Epub 2009 Jun 23. Review.

PMID:
19558376
11.

Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.

Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG.

Biol Blood Marrow Transplant. 2010 Feb;16(2):287-91. doi: 10.1016/j.bbmt.2009.10.008. Epub 2009 Oct 14.

12.

Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients.

Barker JN, Martin PL, Coad JE, DeFor T, Trigg ME, Kurtzberg J, Weisdorf DJ, Wagner J.

Biol Blood Marrow Transplant. 2001;7(7):395-9.

13.

The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.

Yamamoto N, Nishimura N, Takeuchi M, Ito T, Yokozaki H, Hirase S, Kubokawa I, Mori T, Yanai T, Hayakawa A, Takeshima Y, Nishio H, Matsuo M, Imadome K, Iijima K.

Eur J Pediatr. 2014 Dec;173(12):1615-8. doi: 10.1007/s00431-013-2181-6. Epub 2013 Oct 30.

PMID:
24169729
14.

Successful Preemptive Therapy with single dose Rituximab for Epstein-Barr Virus Infection to Prevent Post-Transplant-Lymphoproliferative Disease after Pediatric Hematopoietic Stem Cell Transplantation.

Kim BK, Kang HJ, Hong KT, An HY, Choi JY, Lee JS, Park SS, Shin HY.

Transpl Infect Dis. 2019 Sep 26:e13182. doi: 10.1111/tid.13182. [Epub ahead of print]

PMID:
31556214
15.

Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.

Carpenter B, Haque T, Dimopoulou M, Atkinson C, Roughton M, Grace S, Denovan S, Fielding A, Kottaridis PD, Griffiths P, Mackinnon S, Emery V, Chakraverty R.

Transplantation. 2010 Sep 15;90(5):564-70. doi: 10.1097/TP.0b013e3181e7a3bf.

PMID:
20555307
16.

Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.

Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.

Biol Blood Marrow Transplant. 2011 Jun;17(6):901-7. doi: 10.1016/j.bbmt.2010.10.003. Epub 2010 Oct 13.

17.

Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.

Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A, Levis A.

Clin Transplant. 2013 Jul-Aug;27(4):E491-7. doi: 10.1111/ctr.12172. Epub 2013 Jun 19.

PMID:
23781897
18.

Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.

Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME, Barberi W, Moretta A, Labirio M, Paulli M, Furione M, Maccario R, Locatelli F.

Am J Transplant. 2007 Jun;7(6):1648-55.

19.

Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.

Kinch A, Hallböök H, Arvidson J, Sällström K, Bondeson K, Pauksens K.

Leuk Lymphoma. 2018 May;59(5):1172-1179. doi: 10.1080/10428194.2017.1365860. Epub 2017 Aug 23.

PMID:
28831836
20.

Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.

Raberahona M, Wackenheim C, Germi R, Carré M, Bulabois CE, Thiébaut A, Lupo J, Semenova T, Cahn JY, Morand P, Epaulard O.

Transpl Infect Dis. 2016 Dec;18(6):889-895. doi: 10.1111/tid.12618. Epub 2016 Nov 24.

PMID:
27696681

Supplemental Content

Support Center